Innovent Biologics Announces Initial Data of IBI3003 Clinical Trial
Innovent Biologics announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled receptor C5D, B-cell maturation antigen, and CD3 for the treatment of relapsed or refractory multiple myeloma, in an oral presentation at the 2025 American Society of Hematology Annual Meeting. IBI3003 demonstrated favorable tolerability and a manageable safety profile. Despite the relatively short follow-up duration, IBI3003 has shown encouraging efficacy signals, particularly in high-risk patients with extramedullary disease or those who have previously received anti-BCMA and/or anti-GPRC5D targeted therapies. Encouraging efficacy was observed with a median follow-up of 3.25 months: Among patients treated with greater than or equal to120 undefined/kg, the overall response rate was 83.3%, including 4 cases of stringent complete response, 7 cases of very good partial response, and 9 cases of partial response. Among patients treated with greater than or equal to120 undefined/kg, the ORR was 80% in 10 patients with EMD and 77.8% in 9 patients who had previously received anti-BCMA and/or anti-GPRC5D therapies. Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing testing, the minimal residual disease negativity rate was 100%
Trade with 70% Backtested Accuracy
Analyst Views on 01801
About the author
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Resumes Coverage of INNOVENT BIO with Overweight Rating; Key Catalysts for CN Biotech Sector Expected in Second Half of 2026
China's Biotech Sector Outlook: Morgan Stanley reports that China's biotech sector is stabilizing with a resilient innovation base and ongoing financing recovery, but faces challenges due to geopolitical uncertainties and limited investment themes in 1H26.
Market Fluctuations and Future Growth: The sector is expected to experience range-bound fluctuations in 1H26, with potential for clearer stock price direction in 2H26 as meaningful data releases and licensing transactions emerge.
Investment Strategy: A broader de-risking sector rotation is anticipated, putting pressure on high Beta biotech sectors, while capital reallocation and favorable valuations may support future growth.
Coverage on INNOVENT BIO: Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, along with adjustments to target prices for other stocks.
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.
<Full-day Summary> HSI Falls by 491 Points; HSTI Declines by 114 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, MTR CORPORATION, SINOPHARM Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.
Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.
Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.
<Midday Update> HSI Falls 523 Points; HSTI Declines 127 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, SINOPHARM, KB LAMINATES Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 523 points (1.9%) to 26,558, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.4% and 2.1%, respectively.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and Alibaba saw significant drops, with Meituan down 4.8% and Tencent down 3.4%, amidst high short selling ratios.
Notable Declines in Constituents: Several constituents, including Hansoh Pharma and Sino Biopharma, reported steep declines, with Hansoh Pharma down 6.5% and Sino Biopharma down 6.1%.
Gainers Amidst Losses: Despite the overall market downturn, a few stocks like WH Group and Henderson Land recorded gains, with WH Group up 3.2% and Henderson Land up 1.7%, both hitting new highs.
HSI Drops Over 500 Points; Meituan, Chinese Insurers and Pharmacies Underperform; Standard Chartered Remains Strong; Knowledge Atlas and MiniMax Recover
Market Overview: The Hong Kong bourse opened lower, with the Hang Seng Index (HSI) dropping 509 points or 1.9% to 26,572, amid a turnover of HKD124.419 billion.
Pharmaceutical Sector Decline: Pharmaceutical stocks were the biggest losers, with notable declines in HANSOH PHARMA, SINO BIOPHARM, and CSPC PHARMA, all experiencing significant short selling.
Insurance Sector Struggles: Chinese insurers faced pressure, with major companies like CHINA LIFE and PING AN seeing substantial losses, contributing to a broader decline in the financial sector.
AI Stocks Recovery: Three AI-related semi-IPOs rebounded after previous losses, with MINIMAX-WP, KNOWLEDGE ATLAS, and HAIZHI TECH GP all posting gains and increased trading volumes.
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Resumes Coverage of INNOVENT BIO with Overweight Rating; Key Catalysts for CN Biotech Sector Expected in Second Half of 2026
China's Biotech Sector Outlook: Morgan Stanley reports that China's biotech sector is stabilizing with a resilient innovation base and ongoing financing recovery, but faces challenges due to geopolitical uncertainties and limited investment themes in 1H26.
Market Fluctuations and Future Growth: The sector is expected to experience range-bound fluctuations in 1H26, with potential for clearer stock price direction in 2H26 as meaningful data releases and licensing transactions emerge.
Investment Strategy: A broader de-risking sector rotation is anticipated, putting pressure on high Beta biotech sectors, while capital reallocation and favorable valuations may support future growth.
Coverage on INNOVENT BIO: Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, along with adjustments to target prices for other stocks.
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.
<Full-day Summary> HSI Falls by 491 Points; HSTI Declines by 114 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, MTR CORPORATION, SINOPHARM Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.
Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.
Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.
<Midday Update> HSI Falls 523 Points; HSTI Declines 127 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, SINOPHARM, KB LAMINATES Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 523 points (1.9%) to 26,558, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.4% and 2.1%, respectively.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and Alibaba saw significant drops, with Meituan down 4.8% and Tencent down 3.4%, amidst high short selling ratios.
Notable Declines in Constituents: Several constituents, including Hansoh Pharma and Sino Biopharma, reported steep declines, with Hansoh Pharma down 6.5% and Sino Biopharma down 6.1%.
Gainers Amidst Losses: Despite the overall market downturn, a few stocks like WH Group and Henderson Land recorded gains, with WH Group up 3.2% and Henderson Land up 1.7%, both hitting new highs.
HSI Drops Over 500 Points; Meituan, Chinese Insurers and Pharmacies Underperform; Standard Chartered Remains Strong; Knowledge Atlas and MiniMax Recover
Market Overview: The Hong Kong bourse opened lower, with the Hang Seng Index (HSI) dropping 509 points or 1.9% to 26,572, amid a turnover of HKD124.419 billion.
Pharmaceutical Sector Decline: Pharmaceutical stocks were the biggest losers, with notable declines in HANSOH PHARMA, SINO BIOPHARM, and CSPC PHARMA, all experiencing significant short selling.
Insurance Sector Struggles: Chinese insurers faced pressure, with major companies like CHINA LIFE and PING AN seeing substantial losses, contributing to a broader decline in the financial sector.
AI Stocks Recovery: Three AI-related semi-IPOs rebounded after previous losses, with MINIMAX-WP, KNOWLEDGE ATLAS, and HAIZHI TECH GP all posting gains and increased trading volumes.
